Tryptamine Therapeutics Doses First Patient in IV-infused Psilocin Phase 1b Study

Investing.com Nov 22 07:10

Tryptamine to Plug $6M Placement Funding Into Acceleration of IV-infused Psilocybin Treatment Trials

The Market HeraldOct 30 07:59

Tryptamine Therapeutics A$6 Million Placement Cornerstoned by Merchant Biotech Fund and Dr Daniel Tillett | ASX:TYP, OTC:TYPTF

Proactive InvestorsOct 30 07:49

Just the Facts: Tryptamine Therapeutics' TRP-8803 Clears Phase 1b Safety Trial | ASX:TYP, OTC:TYPTF

Proactive InvestorsOct 18 20:17

Tryptamine Therapeutics Psilocybin Asset TRP-8803 Clears Safety Test Following Phase 1b Trial

Investing.com Oct 18 07:21

Tryptamine Therapeutics Ltd: Annual Report to shareholders

ASXSep 30 16:21 · Announcements